A Phase 3 interventional study of Methadone and Morphine in Pain, Postoperative, Pain, Acute and Pain, Chronic, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Chinese University of Hong Kong · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing methadone in Pain, Postoperative — 8 open to participants now, 8 under way, 3 of them phase 3. Methadone · Pain, Postoperative.
Among the 37 studies testing methadone in Pain, Postoperative, this one is the 15th largest by enrollment, is one of 3 that started in 2023, is one of 7 in phase 3, and was the 27th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →8 of the 37 studies testing methadone in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:
Brandon Knopp · Sites in United States
Ages 18–120
Medical University of South Carolina · Sites in United States
Ages 18–75
Medical University of South Carolina · Sites in United States
Ages 18–75
The Cleveland Clinic · Sites in United States
Ages 18–72 · Healthy volunteers
Duke University · Sites in United States
Ages 3–17 · Healthy volunteers
By country, each count listing its studies:
Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 7 · Phase 4 21
First in 2009; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 75 across the 37 interventional studies. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 37 has an industry lead sponsor. The 10 most frequent:
Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Chinese University of Hong Kong has 7 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
5 of the studies testing methadone in Pain, Postoperative that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226076Phase 3Medical University of South CarolinaMethadone in TKA for Post-op Pain and Opioid Reduction | 2026-12-28 |
| NCT07565870Phase 3Alexandre P. JoostenMethadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY) | 2026-12-31 |
| NCT07227064Phase 3Medical University of South CarolinaMethadone in THA for Post-op Pain and Opioid Reduction | 2026-12-31 |
| NCT07517679Brandon KnoppMethadone for Post-operative Spine Surgery | 2027-04 |
| NCT07222072The Cleveland ClinicMethadone to Reduce Chronic Opioid Use After Major Spine Surgery: The MEND Pilot Feasibility Study | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies testing methadone in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Despite modern day improvements in pain treatment and availability of different analgesic modalities, suboptimal postoperative pain control remains an issue in cardiac surgical patients. Poorly controlled acute postoperative pain is associated with adverse physiological outcomes that impair the recovery of cardiac surgical patients. It is associated with decreased patient satisfaction, delayed postoperative ambulation, and the development of chronic postsurgical pain (CPSP).
Intravenous opioids such as fentanyl and morphine have been the mainstay of perioperative analgesia for cardiac surgery, either by intermittent boluses by healthcare staff or through a patient-controlled device (PCA). The primary problem with this mechanism of delivery is that significant fluctuations in serum opioid concentrations can occur, resulting in effects which range from inadequate analgesia to overdose and respiratory depression. In contrast to intermittent administration of short-acting opioids such as morphine and fentanyl, a single dose administration of methadone can be considered.
Despite modern day improvements in pain treatment and availability of different analgesic modalities, suboptimal postoperative pain control remains an issue in cardiac surgical patients. Acute postoperative pain is common among cardiac surgical patients, particularly within the first 2 days after surgery, with reported at least moderate intensity. There could be many facets for postoperative pain after adult cardiac surgery. Pain can be caused by surgical incisions and dissections, sternal fracture or incomplete bone healing, multiple drainage cannulas and chest tubes and sternal wound infections. Poorly controlled acute postoperative pain is associated with adverse physiological outcomes that impair the recovery of cardiac surgical patients. It is associated with decreased patient satisfaction, delayed postoperative ambulation, and the development of chronic postsurgical pain (CPSP). The association between sternotomy pain and pulmonary complications has been observed, and the sympathetic activation secondary to pain can induce myocardial ischemia and arrhythmias. Pain control has also been pointed out as one of the major concerns to cardiac surgical patients in intensive care unit. Therefore, optimal acute pain control not only can improve clinical outcomes, but also improves patient satisfaction after cardiac surgery.
Postoperative pain that persists beyond the normal time for tissue healing is increasingly recognized as an important complication after various types of surgery. According to the International Association for Study of Pain, CPSP is defined as the persistence of pain at surgical site or referred area, at least 3 months following the surgical procedure. CPSP is common after cardiac surgery. The reported incidence was 28% to 56% up to 2 years postoperatively. Several mechanisms have been involved in the development of chronic pain after sternotomy. These include dissection, nerve entrapment by sternal wires, sternal retraction, ribs fractures, and intercostal neuralgia as a consequence of nerve damage during dissection of the internal mammary artery during coronary artery bypass graft (CABG). In addition, poorly controlled pain has been a general risk factor for the development of CPSP. All can stimulate the release of pro-inflammatory cytokines which sensitize the afferent nociceptive fibres to cause chronic pain. CPSP has the potential to impact daily functioning and quality of life of patients, as well as increasing the healthcare costs. CARDpain study reported that among those with CPSP, over 50% had significant pain-related interferences with activities of daily living (family and home responsibilities, recreation and employment) at 3, 6 and 12 months following cardiac surgery. Therefore, apart from optimal acute pain control, it is equally important to prevent and manage CPSP, to ensure better satisfaction and quality of lives for our patients.
Intravenous opioids such as fentanyl and morphine have been the mainstay of perioperative analgesia for cardiac surgery, either by intermittent boluses by healthcare staff or through a patient-controlled device (PCA). The primary problem with this mechanism of delivery is that significant fluctuations in serum opioid concentrations can occur, resulting in effects which range from inadequate analgesia to overdose and respiratory depression. These peaks and troughs of analgesia that occur with intermittent opioids administration may explain the suboptimal pain control during the initial postoperative period. In contrast to intermittent administration of short-acting opioids such as morphine and fentanyl, a single dose administration of methadone can be considered. Methadone was conventionally used in cancer and chronic pain management. It can be administered via oral, intravenous, and other parenteral routes. Despite being an often-used alternative to morphine, it remains relatively invisible in perioperative settings. Methadone is a unique opioid that may provide several important potential benefits for surgical patients in the perioperative period. It is a potent mu receptor agonist with a rapid onset and longest half-life (24-36 hours) of the clinically used opioids. According to a pharmacokinetic study, central nervous system effect site methadone concentration rapidly equilibrates with plasma concentrations, evidenced by a short lag time between plasma concentrations and effects (t1/2ke0 4min). This is comparable to the rapid onset and effect compartment equilibration of fentanyl and sulfentanil (5-6min), and in contrast the slow onset time of morphine, where t1/2ke0 has been reported to exceed 4 hours. In addition, as reviewed in an editorial, when methadone is administered at a dose of 20mg or higher, the duration of analgesia approximates the half-life of 24-36 hours. Therefore, a single intravenous dose 20mg administered to an adult at induction of anaesthesia should provide a rapid onset and significant pain relief up to 1-2 days postoperatively, which is the period reported to have the highest pain score after cardiac surgery. Methadone is also a N-methyl-D-aspartate (NMDA) receptor antagonist. It has been reported to possess anti-hyperanalgesic and anti-allodynic properties, that is important in preventing pain sensitization and the development of CPSP, which is of high risk in cardiac surgical patients.
There have been few randomized controlled trials comparing between intravenous methadone and other opioids for perioperative pain control in cardiac surgery requiring sternotomy, and none in the Asian populations. In addition, the effect of methadone on chronic postsurgical pain in cardiac surgical patients has not been widely reported in literature. Therefore, the primary aim of this pilot randomized controlled trial is a feasibility study to evaluate the protocol and the effect of methadone on acute and chronic pain control after open cardiac surgery, compared with conventional approach of opioid-based analgesia using morphine and fentanyl. In addition, the effects of methadone on opioids consumption, opioid-related side effects, patient satisfaction, postoperative extubation times, and length of stay in hospital and ICU will be determined. The investigators hypothesized that intravenous methadone is associated with a reduction in opioids requirement intraoperatively and in the first 24 hours after surgery, and improvement in acute pain score at 12h after extubation. The secondary hypothesis is that patients administered with methadone would experience less CPSP compared with standard treatment group.
The investigators hypothesized that intravenous methadone is feasible and applicable in cardiac anaesthesia, and is associated with opioid-sparing intraoperatively and within 24h after surgery, as well as better acute and chronic pain control when compared to conventional opioid-based approach with morphine and fentanyl in adult cardiac surgical patients. The aims of the study are as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Upon induction of anaesthesia, intravenous methadone 0.2mg/kg (maximum dose 20mg) in blind labelling will be administered by infusion over 30 minutes. No further morphine will be given throughout the operation, but administration of Intraoperative fentanyl will be left to the discretion of the attending anaesthesiologists
Drug: Methadone
Upon induction of anaesthesia, intravenous morphine that is of equipotent dose as 0.2mg/kg methadone or 20mg methadone if maximum dose of interventional drug is reached) in blind labelling will be administered by infusion over 30 minutes. No further morphine will be given throughout the operation, but administration of Intraoperative fentanyl will be left to the discretion of the attending anaesthesiologists
Drug: Morphine
The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
Proportion of patients that can be recruited
defined as the number of patients that fit the recruitment criteria divided by the total number of elective cardiac surgical patients over a period of time
Time frame: At recruitment
Proportion of patients excluded based on inclusion and exclusion criteria
Number of patients excluded divided by the total number of elective cardiac surgical patients over a period of time
Time frame: At recruitment
Cardiac arrhythmia from side effects of methadone
New-onset cardiac arrhythmia or prolonged QTc attributed to methadone
Time frame: intraoperatively
Cardiac arrhythmia from side effects of methadone
New-onset cardiac arrhythmia or prolonged QTc attributed to methadone
Time frame: Within 72 hours postoperatively
Ventilator time
The time at which the patient is successfully weaned to spontaneous breathing according to ICU ASV protocol
Time frame: Within 24 postoperatively in ICU
Total morphine consumption
Morphine consumption within 24 hours after operation
Time frame: intraop and postop within 24 hours
Intraoperative fentanyl consumption
Fentanyl consumption intraoperatively
Time frame: intraoperative
Pain score at rest
Measured using numerical rating scale. It ranges from 0-10. The higher the score, the worse the pain
Time frame: Within 72 hours postop
Pain score on exertion
Measured using numerical rating scale
Time frame: within 72 hours postop
Time to first morphine rescue
This is the time the patient feels the need to use morphine from patient-controlled analgesia machine
Time frame: Postoperatively up to 24 hours
Nausea and vomiting
Number of episodes of postoperative nausea and vomiting
Time frame: Postoperative within 72 hours
Length of hospital stay
Number of hours the patient has to stay in hospital
Time frame: upon discharge from hospital (assessed up to day 10)
Length of ICU stay
Number of hours the patient has to stay in ICU
Time frame: Upon discharge from ICU (assessed up to day 2)
BPI at 3 months
Measured using Brief Pain Inventory which consists of pain measurement that affects daily living from scale 0-10. The higher the score, the worse the pain
Time frame: At 3 months postop
BPI at 6 months
Measured using Brief Pain Inventory which consists of pain measurement that affects daily living from scale 0-10. The higher the score, the worse the pain
Time frame: At 6 months postop
NPQ at 3 months
Measured using Neuropathic Pain Questionnaire that has scale 0-100. The higher the score, the worse the pain
Time frame: At 3 months postop
NPQ at 6 months
Measured using Neuropathic Pain Questionnaire that has scale 0-100. The higher the score, the worse the pain
Time frame: At 6 months postop
PCS at 3 months
Measured using Pain Catastrophizing Scale. It consists of 13 items with each item scaled 0-4. The higher the score, the worse the pain
Time frame: At 3 months postop
PCS at 6 months
Measured using Pain Catastrophizing Scale. It consists of 13 items with each item scaled 0-4. The higher the score, the worse the pain
Time frame: At 6 months postop
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2023 to primary completion in Dec 2024, 22 months.
Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 22 months is close to that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: start Jan 2024 → Jan 2023, primary completion Feb 2026 → Dec 2024 and completion Apr 2026 → Dec 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methadone
Chinese University of Hong Kong →